Covid-19: 10 Crore Doses of SII's Covovax Approved for Exports by Govt Lab, Stock Rolled Out for Teens
News 18The country’s apex laboratory has cleared more than 10 crore doses of Covovax, another Covid-19 vaccine by the Serum Institute of India, for exports even as India gears up to roll out the shots to inoculate teenagers, News18.com has learnt. According to government data, the Central Drugs Laboratory in Kasauli, Himachal Pradesh has so far approved a little over 10 crore doses of Covovax for the purpose of exports as the vaccine was facing delay in approvals in India. While Adar Poonawalla, Chief Executive Officer of Pune-based vaccine maker SII, blamed the government for the delay in launch of his vaccine Covovax, he emphasised that it is the only vaccine manufactured in India that is also sold in Europe and has an efficacy of 90%. “Till now, around 10 crore doses, which started flowing into the laboratory from October-November, have been cleared for exports to several countries, including Indonesia and Philippines.” On Tuesday, Poonawalla announced on Twitter that Covovax has been approved for administration to children in the 12-17 age group.